secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0000950170-24-119791
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q3 2024 revenue up 35% to $18.2M; lung diagnostic revenue grows 40% YoY
--------------------------------------------------------------------------------

- Total revenue $18.2M (+35% YoY); lung diagnostic revenue $17.2M (+40% YoY).
- Net loss improved 6% to $10.3M; Adjusted EBITDA loss $5.6M.
- Gross profit margin 77.0% vs 76.1% in Q3 2023; test volume 13,900 (+34% YoY).
- Reiterated FY 2024 revenue guidance $70M-$72M; targeting Adjusted EBITDA profitability H2 2025.
- Presented Nodify XL2/CDT data at CHEST; launched CLARIFY study for diverse patient data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024119791/0000950170-24-119791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024119791/bdsx-20241101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-119791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer